Nascent Therapeutics provides medicines that address mitochondrial biology and disease.
Nascent Therapeutics has raised $676K in total funding. The most recent round was Pre-Seed. The last funding was announced in September 2026.
Nascent Therapeutics's investors include Zinc, Medicines Discovery Catapult.
Nascent Therapeutics is headquartered in Cambridge, United Kingdom.
Nascent Therapeutics provides medicines that address mitochondrial biology and disease.
Nascent Therapeutics is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nascent Therapeutics — Funding & Investors." VCBacked, September 3, 2026, https://www.vcbacked.co/company/nascent-therapeutics. Accessed October 1, 2026.
VCBacked. (2026). Nascent Therapeutics — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/nascent-therapeutics
{{cite web |title=Nascent Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nascent-therapeutics |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated